COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.

Conforti, Claudio; Giuffrida, Roberta; Dianzani, Caterina; Di Meo, Nicola; Zalaudek, Iris

Conforti, Claudio; Giuffrida, Roberta; Dianzani, Caterina; Di Meo, Nicola; Zalaudek, Iris.

Conforti C; Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
Giuffrida R; Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Messina, Italy.
Dianzani C; Department of Plastic, Reconstructive and Cosmetic Surgery, Dermatology Section, Campus Bio-Medico University Hospital, Rome, Italy.
Di Meo N; Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
Zalaudek I; Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.

Dermatol Ther ; 33(4): e13298, 2020 07.

Article in English | MEDLINE | ID: covidwho-7407

Subject(s)

Coronavirus Infections/complications; Immunosuppressive Agents/administration & dosage; Pneumonia, Viral/complications; Psoriasis/drug therapy; COVID-19; Coronavirus Infections/epidemiology; Humans; Immunosuppressive Agents/adverse effects; Pandemics; Pneumonia, Viral/epidemiology; Psoriasis/complications; Risk Factors

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Psoriasis / Coronavirus Infections / Immunosuppressive Agents Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2020 Document Type: Article Affiliation country: Dth.13298

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google